Table 3.

Meta-analysis of rate of G3-5 DRAEs, pneumonitis and drug-related death in combination therapy

Combination regimens	Items for evaluation	Rate (%)	95% CI
Anti-PD-1/L1 antibody therapy in combination with ipilimumab (IPI)	Rate of G3–5 DRAEs	31	23–39%
	Rate of pneumonitis	3	2–4%
	Rate of drug-related death	1	1–2%
Anti-PD-1/L1 antibody therapy in combination with chemotherapy	Rate of G3–5 DRAEs	41	34–48%
	Rate of pneumonitis	2	1–3%
	Drug-related death	3	0–5%
Anti-PD-1/L1 antibody therapy in combination with EGFR-TKIs	Rate of G3–5 DRAEs	41	20–62%
	Rate of pneumonitis	3	−1–7%
	Drug-related death	1	−3–6%
Anti-PD-1/L1 antibody therapy in combination with IDO inhibitors	Rate of G3–5 DRAEs	16	5–27%
	Rate of pneumonitis	9	1–18%
Drug-related death	-	-